ID: hyp-SDA-2026-04-08-gap-debate-20260406-0
Hypothesis
Light-Independent Chronopharmacology
Small molecules targeting casein kinase 1 to directly entrain peripheral circadian clocks in brain microglia without light input or sleep modifications.
EvidencePending (0%)📖 1 cit🗣 1 debates✓ 3 support✗ 2 oppose
✓ All Quality Gates Passed
🧪 Overview
Small molecules targeting casein kinase 1 to directly entrain peripheral circadian clocks in brain microglia without light input or sleep modifications
🧬 Mechanism
🔗 Mechanism from KG for CSNK1D/CSNK1E
Auto-built from this analysis's top knowledge-graph edges.
graph TD
ARNTL["ARNTL"] -->|transcriptionally| NLRP3["NLRP3"]
circadian_disruption["circadian disruption"] -->|causes| neuroinflammation["neuroinflammation"]
IL1R1["IL1R1"] -->|mediates| Microglial_priming["Microglial priming"]
anti_TNF_drugs["anti-TNF drugs"] -->|targets| neuroinflammation_1["neuroinflammation"]
inflammation["inflammation"] -->|causes| Microglial_priming_2["Microglial priming"]
microglial_priming["microglial_priming"] -->|causes| neurodegeneration["neurodegeneration"]
NR1D1["NR1D1"] -->|represses| NFKB1["NFKB1"]
IL1R1_3["IL1R1"] -->|mediates| microglial_priming_4["microglial_priming"]
circadian_disruption_5["circadian_disruption"] -->|causes| neuroinflammation_6["neuroinflammation"]
CSNK1D["CSNK1D"] -->|phosphorylates| PER1["PER1"]
MMP9["MMP9"] -->|remodels| extracellular_matrix["extracellular_matrix"]
IL1R1_7["IL1R1"] -->|modulates| positive_feedback_loops["positive_feedback_loops"]
style ARNTL fill:#ce93d8,stroke:#333,color:#000
style NLRP3 fill:#ce93d8,stroke:#333,color:#000
style circadian_disruption fill:#4fc3f7,stroke:#333,color:#000
style neuroinflammation fill:#4fc3f7,stroke:#333,color:#000
style IL1R1 fill:#ce93d8,stroke:#333,color:#000
style Microglial_priming fill:#4fc3f7,stroke:#333,color:#000
style anti_TNF_drugs fill:#4fc3f7,stroke:#333,color:#000
style neuroinflammation_1 fill:#4fc3f7,stroke:#333,color:#000
style inflammation fill:#4fc3f7,stroke:#333,color:#000
style Microglial_priming_2 fill:#4fc3f7,stroke:#333,color:#000
style microglial_priming fill:#4fc3f7,stroke:#333,color:#000
style neurodegeneration fill:#ef5350,stroke:#333,color:#000
style NR1D1 fill:#ce93d8,stroke:#333,color:#000
style NFKB1 fill:#ce93d8,stroke:#333,color:#000
style IL1R1_3 fill:#ce93d8,stroke:#333,color:#000
style microglial_priming_4 fill:#4fc3f7,stroke:#333,color:#000
style circadian_disruption_5 fill:#4fc3f7,stroke:#333,color:#000
style neuroinflammation_6 fill:#4fc3f7,stroke:#333,color:#000
style CSNK1D fill:#ce93d8,stroke:#333,color:#000
style PER1 fill:#ce93d8,stroke:#333,color:#000
style MMP9 fill:#ce93d8,stroke:#333,color:#000
style extracellular_matrix fill:#81c784,stroke:#333,color:#000
style IL1R1_7 fill:#ce93d8,stroke:#333,color:#000
style positive_feedback_loops fill:#4fc3f7,stroke:#333,color:#000⚖️ Evidence
⚖️ Evidence Matrix3 supports0 contradicts
Supports
Casein kinase 1δ (CSNK1D) inhibitors show promise as therapeutic agents for neurodegenerative disorders, providing direct pharmacological validation of CSNK1D/CSNK1E as light-independent chronopharmacological targets in brain disease.
Supports
Isoform-specific C-terminal autoinhibitory phosphorylation governs the circadian period-lengthening activity of CK1 (CSNK1D/CSNK1E), providing mechanistic rationale for isoform-selective pharmacological targeting without requiring light-cycle input.
📖 Linked Papers
No linked papers recorded for this hypothesis yet.
🏥 Translation
🧬 3D Protein Structure — CSNK1D
No curated PDB or AlphaFold mapping for CSNK1D yet. Search RCSB →
💉 Clinical Trials
No clinical trials data linked to this hypothesis yet.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for CSNK1D.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
🏆 Tournament
🏆 Arenas / Elo
No arena matches recorded yet. Browse Arenas →
📊 Market Indicators
7d Trend
↔
Stable
7d Momentum
▲ 0.0%
Volatility
High
0.0535
Events (7d)
0
Price History
▲6.0%💾 Resource Usage
LLM Tokens
10,654
$0.0639
Total Cost
$0.0639
🔮 Predictions
🔎 Predictions vs Observations2 predictions · 0 with recorded observations
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| IF CSNK1 inhibitor is administered at 6 different circadian time points (CT2, CT6, CT10, CT14, CT18, CT22) THEN a dose-dependent Phase Response Curve (PRC) will be generated showing predictable phase | Maximum phase advance of 3.5±0.8h at CT18-20 and maximum phase delay of 4.2±1.1h at CT8-10; PRC amplitude >2x baseline rhythm amplitude; ED50 < 500nM for CSNK1 | — no observation — | pending | 0.70 |
| IF pharmacological CSNK1 inhibitor (PF-670462, 10mg/kg, i.p.) is administered to adult mice during constant darkness THEN a measurable phase shift in microglial PER2::LUC bioluminescence will be obser | Phase shift of 2-6 hours in microglial PER2::LUC peak expression relative to vehicle controls, with significant changes in BMAL1::LUC anti-phase oscillations (p | — no observation — | pending | 0.75 |
🔮 Falsifiable Predictions (2)
pendingconf 75%
IF pharmacological CSNK1 inhibitor (PF-670462, 10mg/kg, i.p.) is administered to adult mice during constant darkness THEN a measurable phase shift in microglial PER2::LUC bioluminescence will be observed within 24-48 hours post-injection using ex vivo brain slice cultures from PER2::LUC reporter mic
Predicted outcome: Phase shift of 2-6 hours in microglial PER2::LUC peak expression relative to vehicle controls, with significant changes in BMAL1::LUC anti-phase oscil
Falsification: No significant phase shift (<30 min) in microglial circadian bioluminescence rhythms following CSNK1 inhibitor administration compared to vehicle controls at any circadian time tested
pendingconf 70%
IF CSNK1 inhibitor is administered at 6 different circadian time points (CT2, CT6, CT10, CT14, CT18, CT22) THEN a dose-dependent Phase Response Curve (PRC) will be generated showing predictable phase advances during the subjective night (CT18-22) and phase delays during subjective day (CT6-14) withi
Predicted outcome: Maximum phase advance of 3.5±0.8h at CT18-20 and maximum phase delay of 4.2±1.1h at CT8-10; PRC amplitude >2x baseline rhythm amplitude; ED50 < 500nM
Falsification: Absence of a systematic PRC pattern; phase shifts <1 hour regardless of administration time; failure to generate significant phase shifts at doses up to 10μM; or phase shifts that match random/gaussia
▸Metadatasource: v1_phase_c_backfill · origin_type: debate_synthesis
| source | v1_phase_c_backfill |
| origin_type | debate_synthesis |
| _schema_version | 1 |
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
0
0 supporting
0 contradicting
0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.